A multicenter phase 4 geriatric assessment directed trial to evaluate gemcitabine +/− nab-paclitaxel in elderly pancreatic cancer patients (GrantPax)

A multicenter phase 4 geriatric assessment directed trial to evaluate gemcitabine +/− nab-paclitaxel in elderly pancreatic cancer patients (GrantPax)

Abstract Background In the group of elderly patients (≥70 years) with metastatic pancreatic ductal adenocarcinoma (mPDAC), it is not known who benefits from intensive 1st line nab-paclitaxel/gemcitabine (nab-p/gem) combination chemotherapy or who would rather suffer from increased toxicity. We aim t...

Full description

Bibliographic Details
Main Authors: Johannes Betge, Jing Chi-Kern, Nadine Schulte, Sebastian Belle, Tobias Gutting, Elke Burgermeister, Ralf Jesenofsky, Martin Maenz, Ulrich Wedding, Matthias P. Ebert, Nicolai Haertel
Format: Article
Language:English
Published: BMC 2018-07-01
Series:BMC Cancer
Subjects:
Pancreatic cancer
Elderly
Comprehensive geriatric assessment
Nab-paclitaxel
Personalized medicine
Geriatric oncology
Online Access:http://link.springer.com/article/10.1186/s12885-018-4665-2

Internet

http://link.springer.com/article/10.1186/s12885-018-4665-2

Similar Items